A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
Identifieur interne : 000763 ( Main/Corpus ); précédent : 000762; suivant : 000764A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
Auteurs : Olanow ; S. Fahn ; M. Muenter ; H. Klawans ; H. Hurtig ; M. Stern ; I. Shoulson ; R. Kurlan ; J. D. Grimes ; J. Jankovic ; M. Hoehn ; C. H. Markham ; R. Duvisin ; O. Reinmuth ; H. A. Leonard ; E. Ahlskog ; R. Feldman ; L. Hershey ; M. D. YahrSource :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
Abstract
Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.
Url:
DOI: 10.1002/mds.870090107
Links to Exploration step
ISTEX:64D5EE0FDC2B6B390092EB3128575430429F610DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title><author><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">Olanow</name><affiliation><mods:affiliation>Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida</mods:affiliation></affiliation></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S." last="Fahn">S. Fahn</name><affiliation><mods:affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Muenter, M" sort="Muenter, M" uniqKey="Muenter M" first="M." last="Muenter">M. Muenter</name><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</mods:affiliation></affiliation></author><author><name sortKey="Klawans, H" sort="Klawans, H" uniqKey="Klawans H" first="H." last="Klawans">H. Klawans</name><affiliation><mods:affiliation>Department of Neurology, Rush Presbyterian‐St. Luke's Mediacal Center, Chicago, Illinois</mods:affiliation></affiliation></author><author><name sortKey="Hurtig, H" sort="Hurtig, H" uniqKey="Hurtig H" first="H." last="Hurtig">H. Hurtig</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Stern, M" sort="Stern, M" uniqKey="Stern M" first="M." last="Stern">M. Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Grimes, J D" sort="Grimes, J D" uniqKey="Grimes J" first="J. D." last="Grimes">J. D. Grimes</name><affiliation><mods:affiliation>Department of Neurology, Ottawa Civic Hospital, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">J. Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas</mods:affiliation></affiliation></author><author><name sortKey="Hoehn, M" sort="Hoehn, M" uniqKey="Hoehn M" first="M." last="Hoehn">M. Hoehn</name><affiliation><mods:affiliation>Department of Neurology, University of Colorado, Denver, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Markham, C H" sort="Markham, C H" uniqKey="Markham C" first="C. H." last="Markham">C. H. Markham</name><affiliation><mods:affiliation>Department of Neurology, University of California, Los Angeles, California</mods:affiliation></affiliation></author><author><name sortKey="Duvisin, R" sort="Duvisin, R" uniqKey="Duvisin R" first="R." last="Duvisin">R. Duvisin</name><affiliation><mods:affiliation>Department of Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Reinmuth, O" sort="Reinmuth, O" uniqKey="Reinmuth O" first="O." last="Reinmuth">O. Reinmuth</name><affiliation><mods:affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Leonard, H A" sort="Leonard, H A" uniqKey="Leonard H" first="H. A." last="Leonard">H. A. Leonard</name><affiliation><mods:affiliation>The Neurological Clinic, Portland, Oregon</mods:affiliation></affiliation></author><author><name sortKey="Ahlskog, E" sort="Ahlskog, E" uniqKey="Ahlskog E" first="E." last="Ahlskog">E. Ahlskog</name><affiliation><mods:affiliation>Department of neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Feldman, R" sort="Feldman, R" uniqKey="Feldman R" first="R." last="Feldman">R. Feldman</name><affiliation><mods:affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</mods:affiliation></affiliation></author><author><name sortKey="Hershey, L" sort="Hershey, L" uniqKey="Hershey L" first="L." last="Hershey">L. Hershey</name><affiliation><mods:affiliation>Department of Neurology, Buffalo VA Medical Center, Buffalo, New York</mods:affiliation></affiliation></author><author><name sortKey="Yahr, M D" sort="Yahr, M D" uniqKey="Yahr M" first="M. D." last="Yahr">M. D. Yahr</name><affiliation><mods:affiliation>Department of Neurology, Mt. Sinai Medical Center, New York, New York, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:64D5EE0FDC2B6B390092EB3128575430429F610D</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090107</idno><idno type="url">https://api.istex.fr/document/64D5EE0FDC2B6B390092EB3128575430429F610D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000763</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title><author><name sortKey="Olanow" sort="Olanow" uniqKey="Olanow" last="Olanow">Olanow</name><affiliation><mods:affiliation>Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida</mods:affiliation></affiliation></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S." last="Fahn">S. Fahn</name><affiliation><mods:affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York</mods:affiliation></affiliation></author><author><name sortKey="Muenter, M" sort="Muenter, M" uniqKey="Muenter M" first="M." last="Muenter">M. Muenter</name><affiliation><mods:affiliation>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</mods:affiliation></affiliation></author><author><name sortKey="Klawans, H" sort="Klawans, H" uniqKey="Klawans H" first="H." last="Klawans">H. Klawans</name><affiliation><mods:affiliation>Department of Neurology, Rush Presbyterian‐St. Luke's Mediacal Center, Chicago, Illinois</mods:affiliation></affiliation></author><author><name sortKey="Hurtig, H" sort="Hurtig, H" uniqKey="Hurtig H" first="H." last="Hurtig">H. Hurtig</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Stern, M" sort="Stern, M" uniqKey="Stern M" first="M." last="Stern">M. Stern</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Kurlan, R" sort="Kurlan, R" uniqKey="Kurlan R" first="R." last="Kurlan">R. Kurlan</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Grimes, J D" sort="Grimes, J D" uniqKey="Grimes J" first="J. D." last="Grimes">J. D. Grimes</name><affiliation><mods:affiliation>Department of Neurology, Ottawa Civic Hospital, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J." last="Jankovic">J. Jankovic</name><affiliation><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas</mods:affiliation></affiliation></author><author><name sortKey="Hoehn, M" sort="Hoehn, M" uniqKey="Hoehn M" first="M." last="Hoehn">M. Hoehn</name><affiliation><mods:affiliation>Department of Neurology, University of Colorado, Denver, Colorado</mods:affiliation></affiliation></author><author><name sortKey="Markham, C H" sort="Markham, C H" uniqKey="Markham C" first="C. H." last="Markham">C. H. Markham</name><affiliation><mods:affiliation>Department of Neurology, University of California, Los Angeles, California</mods:affiliation></affiliation></author><author><name sortKey="Duvisin, R" sort="Duvisin, R" uniqKey="Duvisin R" first="R." last="Duvisin">R. Duvisin</name><affiliation><mods:affiliation>Department of Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey</mods:affiliation></affiliation></author><author><name sortKey="Reinmuth, O" sort="Reinmuth, O" uniqKey="Reinmuth O" first="O." last="Reinmuth">O. Reinmuth</name><affiliation><mods:affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Leonard, H A" sort="Leonard, H A" uniqKey="Leonard H" first="H. A." last="Leonard">H. A. Leonard</name><affiliation><mods:affiliation>The Neurological Clinic, Portland, Oregon</mods:affiliation></affiliation></author><author><name sortKey="Ahlskog, E" sort="Ahlskog, E" uniqKey="Ahlskog E" first="E." last="Ahlskog">E. Ahlskog</name><affiliation><mods:affiliation>Department of neurology, Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Feldman, R" sort="Feldman, R" uniqKey="Feldman R" first="R." last="Feldman">R. Feldman</name><affiliation><mods:affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</mods:affiliation></affiliation></author><author><name sortKey="Hershey, L" sort="Hershey, L" uniqKey="Hershey L" first="L." last="Hershey">L. Hershey</name><affiliation><mods:affiliation>Department of Neurology, Buffalo VA Medical Center, Buffalo, New York</mods:affiliation></affiliation></author><author><name sortKey="Yahr, M D" sort="Yahr, M D" uniqKey="Yahr M" first="M. D." last="Yahr">M. D. Yahr</name><affiliation><mods:affiliation>Department of Neurology, Mt. Sinai Medical Center, New York, New York, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="volume">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="40">40</biblScope><biblScope unit="page" to="47">47</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">64D5EE0FDC2B6B390092EB3128575430429F610D</idno><idno type="DOI">10.1002/mds.870090107</idno><idno type="ArticleID">MDS870090107</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Levodopa</term><term>Parkinson's disease</term><term>Pergolide</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr. Olanow</name><affiliations><json:string>Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida</json:string></affiliations></json:item><json:item><name>S. Fahn</name><affiliations><json:string>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York</json:string></affiliations></json:item><json:item><name>M. Muenter</name><affiliations><json:string>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</json:string></affiliations></json:item><json:item><name>H. Klawans</name><affiliations><json:string>Department of Neurology, Rush Presbyterian‐St. Luke's Mediacal Center, Chicago, Illinois</json:string></affiliations></json:item><json:item><name>H. Hurtig</name><affiliations><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</json:string></affiliations></json:item><json:item><name>M. Stern</name><affiliations><json:string>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</json:string></affiliations></json:item><json:item><name>I. Shoulson</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>R. Kurlan</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>J. D. Grimes</name><affiliations><json:string>Department of Neurology, Ottawa Civic Hospital, Ontario, Canada</json:string></affiliations></json:item><json:item><name>J. Jankovic</name><affiliations><json:string>Department of Neurology, Baylor College of Medicine, Houston, Texas</json:string></affiliations></json:item><json:item><name>M. Hoehn</name><affiliations><json:string>Department of Neurology, University of Colorado, Denver, Colorado</json:string></affiliations></json:item><json:item><name>C. H. Markham</name><affiliations><json:string>Department of Neurology, University of California, Los Angeles, California</json:string></affiliations></json:item><json:item><name>R. Duvisin</name><affiliations><json:string>Department of Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey</json:string></affiliations></json:item><json:item><name>O. Reinmuth</name><affiliations><json:string>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</json:string></affiliations></json:item><json:item><name>H. A. Leonard</name><affiliations><json:string>The Neurological Clinic, Portland, Oregon</json:string></affiliations></json:item><json:item><name>E. Ahlskog</name><affiliations><json:string>Department of neurology, Mayo Clinic, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>R. Feldman</name><affiliations><json:string>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</json:string></affiliations></json:item><json:item><name>L. Hershey</name><affiliations><json:string>Department of Neurology, Buffalo VA Medical Center, Buffalo, New York</json:string></affiliations></json:item><json:item><name>M. D. Yahr</name><affiliations><json:string>Department of Neurology, Mt. Sinai Medical Center, New York, New York, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Pergolide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Levodopa</value></json:item></subject><articleId><json:string>MDS870090107</json:string></articleId><language><json:string>eng</json:string></language><abstract>Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.</abstract><qualityIndicators><score>6.231</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 828 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1046</abstractCharCount><pdfWordCount>4479</pdfWordCount><pdfCharCount>29696</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>146</abstractWordCount></qualityIndicators><title>A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>9</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>47</last><first>40</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1994</publicationDate><copyrightDate>1994</copyrightDate><doi><json:string>10.1002/mds.870090107</json:string></doi><id>64D5EE0FDC2B6B390092EB3128575430429F610D</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/64D5EE0FDC2B6B390092EB3128575430429F610D/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/64D5EE0FDC2B6B390092EB3128575430429F610D/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/64D5EE0FDC2B6B390092EB3128575430429F610D/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>1994</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title><author><persName><surname>Olanow</surname></persName><roleName type="degree">Dr.</roleName><note type="correspondence"><p>Correspondence: 4 Columbia Drive, #410, Tampa, FL 33606, U.S.A.</p></note><affiliation>Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida</affiliation></author><author><persName><forename type="first">S.</forename><surname>Fahn</surname></persName><affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York</affiliation></author><author><persName><forename type="first">M.</forename><surname>Muenter</surname></persName><affiliation>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</affiliation></author><author><persName><forename type="first">H.</forename><surname>Klawans</surname></persName><affiliation>Department of Neurology, Rush Presbyterian‐St. Luke's Mediacal Center, Chicago, Illinois</affiliation></author><author><persName><forename type="first">H.</forename><surname>Hurtig</surname></persName><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</affiliation></author><author><persName><forename type="first">M.</forename><surname>Stern</surname></persName><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</affiliation></author><author><persName><forename type="first">I.</forename><surname>Shoulson</surname></persName><affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</affiliation></author><author><persName><forename type="first">R.</forename><surname>Kurlan</surname></persName><affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</affiliation></author><author><persName><forename type="first">J. D.</forename><surname>Grimes</surname></persName><affiliation>Department of Neurology, Ottawa Civic Hospital, Ontario, Canada</affiliation></author><author><persName><forename type="first">J.</forename><surname>Jankovic</surname></persName><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas</affiliation></author><author><persName><forename type="first">M.</forename><surname>Hoehn</surname></persName><affiliation>Department of Neurology, University of Colorado, Denver, Colorado</affiliation></author><author><persName><forename type="first">C. H.</forename><surname>Markham</surname></persName><affiliation>Department of Neurology, University of California, Los Angeles, California</affiliation></author><author><persName><forename type="first">R.</forename><surname>Duvisin</surname></persName><affiliation>Department of Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey</affiliation></author><author><persName><forename type="first">O.</forename><surname>Reinmuth</surname></persName><affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</affiliation></author><author><persName><forename type="first">H. A.</forename><surname>Leonard</surname></persName><affiliation>The Neurological Clinic, Portland, Oregon</affiliation></author><author><persName><forename type="first">E.</forename><surname>Ahlskog</surname></persName><affiliation>Department of neurology, Mayo Clinic, Rochester, Minnesota</affiliation></author><author><persName><forename type="first">R.</forename><surname>Feldman</surname></persName><affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</affiliation></author><author><persName><forename type="first">L.</forename><surname>Hershey</surname></persName><affiliation>Department of Neurology, Buffalo VA Medical Center, Buffalo, New York</affiliation></author><author><persName><forename type="first">M. D.</forename><surname>Yahr</surname></persName><affiliation>Department of Neurology, Mt. Sinai Medical Center, New York, New York, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994"></date><biblScope unit="volume">9</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="40">40</biblScope><biblScope unit="page" to="47">47</biblScope></imprint></monogr><idno type="istex">64D5EE0FDC2B6B390092EB3128575430429F610D</idno><idno type="DOI">10.1002/mds.870090107</idno><idno type="ArticleID">MDS870090107</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1994</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Pergolide</term></item><item><term>Levodopa</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1994">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/64D5EE0FDC2B6B390092EB3128575430429F610D/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="tocForm">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v9:1</doi><numberingGroup><numbering type="journalVolume" number="9">9</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="1994">1994</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.870090107</doi><idGroup><id type="unit" value="MDS870090107"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1994 Movement Disorder Society</copyright><eventGroup><event type="firstOnline" date="2004-10-12"></event><event type="publishedOnlineFinalForm" date="2004-10-12"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:HeaderRef result:HeaderRef" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">40</numbering><numbering type="pageLast">47</numbering></numberingGroup><correspondenceTo>4 Columbia Drive, #410, Tampa, FL 33606, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS870090107.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="44"></count></countGroup><titleGroup><title type="main" xml:lang="en">A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title><title type="short" xml:lang="en">PERGOLIDE AS AN ADJUNCT TO SINEMET®</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr.</honorifics><givenNames>C. W.</givenNames><familyName>Olanow</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>S.</givenNames><familyName>Fahn</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>M.</givenNames><familyName>Muenter</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>H.</givenNames><familyName>Klawans</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>H.</givenNames><familyName>Hurtig</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>M.</givenNames><familyName>Stern</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6"><personName><givenNames>I.</givenNames><familyName>Shoulson</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af6"><personName><givenNames>R.</givenNames><familyName>Kurlan</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af7"><personName><givenNames>J. D.</givenNames><familyName>Grimes</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af8"><personName><givenNames>J.</givenNames><familyName>Jankovic</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af9"><personName><givenNames>M.</givenNames><familyName>Hoehn</familyName></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af10"><personName><givenNames>C. H.</givenNames><familyName>Markham</familyName></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af11"><personName><givenNames>R.</givenNames><familyName>Duvisin</familyName></personName></creator><creator xml:id="au14" creatorRole="author" affiliationRef="#af12"><personName><givenNames>O.</givenNames><familyName>Reinmuth</familyName></personName></creator><creator xml:id="au15" creatorRole="author" affiliationRef="#af13"><personName><givenNames>H. A.</givenNames><familyName>Leonard</familyName></personName></creator><creator xml:id="au16" creatorRole="author" affiliationRef="#af14"><personName><givenNames>E.</givenNames><familyName>Ahlskog</familyName></personName></creator><creator xml:id="au17" creatorRole="author" affiliationRef="#af15"><personName><givenNames>R.</givenNames><familyName>Feldman</familyName></personName></creator><creator xml:id="au18" creatorRole="author" affiliationRef="#af16"><personName><givenNames>L.</givenNames><familyName>Hershey</familyName></personName></creator><creator xml:id="au19" creatorRole="author" affiliationRef="#af17"><personName><givenNames>M. D.</givenNames><familyName>Yahr</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Rush Presbyterian‐St. Luke's Mediacal Center, Chicago, Illinois</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="CA" type="organization"><unparsedAffiliation>Department of Neurology, Ottawa Civic Hospital, Ontario, Canada</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Colorado, Denver, Colorado</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of California, Los Angeles, California</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</unparsedAffiliation></affiliation><affiliation xml:id="af13" countryCode="US" type="organization"><unparsedAffiliation>The Neurological Clinic, Portland, Oregon</unparsedAffiliation></affiliation><affiliation xml:id="af14" countryCode="US" type="organization"><unparsedAffiliation>Department of neurology, Mayo Clinic, Rochester, Minnesota</unparsedAffiliation></affiliation><affiliation xml:id="af15" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</unparsedAffiliation></affiliation><affiliation xml:id="af16" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Buffalo VA Medical Center, Buffalo, New York</unparsedAffiliation></affiliation><affiliation xml:id="af17" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Mt. Sinai Medical Center, New York, New York, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">Pergolide</keyword><keyword xml:id="kwd3">Levodopa</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PERGOLIDE AS AN ADJUNCT TO SINEMET®</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr.</namePart><namePart type="family">Olanow</namePart><affiliation>Department of Neurology and Pharmacology, University of South Florida, Tampa, Florida</affiliation><description>Correspondence: 4 Columbia Drive, #410, Tampa, FL 33606, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Fahn</namePart><affiliation>Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Muenter</namePart><affiliation>Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Klawans</namePart><affiliation>Department of Neurology, Rush Presbyterian‐St. Luke's Mediacal Center, Chicago, Illinois</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Hurtig</namePart><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Stern</namePart><affiliation>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Shoulson</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Kurlan</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J. D.</namePart><namePart type="family">Grimes</namePart><affiliation>Department of Neurology, Ottawa Civic Hospital, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Jankovic</namePart><affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Hoehn</namePart><affiliation>Department of Neurology, University of Colorado, Denver, Colorado</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C. H.</namePart><namePart type="family">Markham</namePart><affiliation>Department of Neurology, University of California, Los Angeles, California</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Duvisin</namePart><affiliation>Department of Neurology, Robert Wood Johnson Medical School, New Brunswick, New Jersey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Reinmuth</namePart><affiliation>Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H. A.</namePart><namePart type="family">Leonard</namePart><affiliation>The Neurological Clinic, Portland, Oregon</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Ahlskog</namePart><affiliation>Department of neurology, Mayo Clinic, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Feldman</namePart><affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Hershey</namePart><affiliation>Department of Neurology, Buffalo VA Medical Center, Buffalo, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. D.</namePart><namePart type="family">Yahr</namePart><affiliation>Department of Neurology, Mt. Sinai Medical Center, New York, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1994</dateIssued><copyrightDate encoding="w3cdtf">1994</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">44</extent></physicalDescription><abstract lang="en">Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Pergolide</topic><topic>Levodopa</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>40</start><end>47</end><total>8</total></extent></part></relatedItem><identifier type="istex">64D5EE0FDC2B6B390092EB3128575430429F610D</identifier><identifier type="DOI">10.1002/mds.870090107</identifier><identifier type="ArticleID">MDS870090107</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1994 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000763 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000763 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:64D5EE0FDC2B6B390092EB3128575430429F610D
|texte= A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |